The Swiss Agency for Therapeutic Products (SwissMedic) has granted Orphan Drug Status (ODS) to 4SC’s Kinselby (resminostat) for the treatment of cutaneous T-cell lymphoma (CTCL). In Switzerland, ODS provides privileged status to drugs that show promise for the treatment of rare diseases and qualifies 4SC for benefits including fee reductions and a faster review process. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!